• Open Access

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study


  • Disclosures Paul Valensi has served as chairman to the advisory board and has given lectures for Novo Nordisk. Janusz Gumprecht and Robert Ligthelm have participated in advisory boards and in speakers’ bureaus for Novo Nordisk. Marian Benroubi, Vito Borzi, Ryuzo Kawamori, Joseph Shaban, Siddharth Shah, Marina Shestakova and Yang Wenying have no conflicts to disclose.

  • Clinical trial registration
    The study is registered with ClinicalTrial.gov and has the following identifier: NCT00659282.

  • Clinical trial data posting
    No results have been posted.

  • Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

Professor Paul Valensi,
Service d’Endocrinologie-Diabétologie-Nutrition, Hôpital Jean Verdier, Avenue du 14 Juillet, 93143 Bondy Cedex, France
Tel.: + 33 1 48 02 65 97
Fax: + 33 1 48 02 63 56
Email: paul.valensi@jvr.aphp.fr


Aims:  The international IMPROVE observational study investigated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30) in the routine treatment of patients with type 2 diabetes. We present analyses for the subgroup of patients who switched from basal insulin to BIAsp 30.

Methods:  Patients in routine care who started insulin therapy with or switched to BIAsp 30 from existing insulin regimens were eligible for this 26-week study. This analysis includes only patients previously treated with basal insulin. Outcomes including adverse events, hypoglycaemic events and glycaemic profile were recorded from patients’ notes, recall and diaries.

Results:  Of the 748 patients included (age 59.7 ± 11.8 years, diabetes duration 11.4 ± 7.3 years, baseline HbA1c 9.1 ± 1.6%), 497 were previously using human neutral protamine Hagedorn (NPH) insulin and 245 analogue basal insulin. Overall, major and minor hypoglycaemia rates decreased from baseline to final visit (major: 0.171 to 0.011; minor: 9.70 to 5.89 events/patient-year) and were similar between the subgroups. HbA1c and fasting blood glucose were significantly reduced from baseline (NPH prestudy: −1.6%, −2.4 mmol/l; analogue basal prestudy: −1.8%, −2.4 mmol/l), as was postprandial blood glucose, with 33.8% of patients achieving the HbA1c target < 7% without hypoglycaemia. Insulin dose increased slightly from prestudy (0.33 ± 0.21 U/kg), baseline (0.40 ± 0.20 U/kg) to final visit (0.52 ± 0.26 U/kg); most patients (76%) followed a twice-daily regimen at final visit. Body weight did not change significantly and treatment satisfaction increased.

Conclusions:  Patients with type 2 diabetes inadequately controlled on basal insulins may improve their glycaemic control by intensification to BIAsp 30 therapy.